What does Jazz Pharma (JAZZ) Combined with GW Pharma (GWPH) Look Like?, PT Raised to $202 at Stifel

April 14, 2021 7:58 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $174.39 +0.90%

Rating Summary:
    32 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Annabel Samimy raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $202.00 (from $195.00) after integrating JAZZ and GW Pharma (NASDAQ: GWPH) models.

The analyst reiterated a Buy rating, stating "We think the addition of GWPH’s Epidiolex for rare childhood epilepsies accelerates its diversification plan and offers another sizable avenue of growth through maximized penetration and geographic expansion. Several questions still linger regarding broad adoption and longevity,
and we highlight these topics within (with KOL/legal checks), but we think these are surmountable. Though Epidiolex dominates the story, JAZZ will continue to develop late-stage nabiximols (currently in 5 Ph.3 trials), with only one successful trial required to support an NDA (approved as Sativex in EU). Consolidated, we think JAZZ has a powerful growth engine, with a now well-diversified portfolio (65% new product contribution by 2022—including JZP-485/ALL-LBL, Xywav/IH approvals in 2021). Our integrated model, with accretion starting in 2022 of $18.48, growing to $20.71 by 2024—more conservative than our initial calculations."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel